Indications Depogestrone
Medroxyprogesterone is used to treat breast cancer during menopause, endometrial hyperplasia and polycystic ovary syndrome. It is used in the treatment of metastatic renal carcinoma, endometrial carcinoma and endometriosis, control of secondary amenorrhea, irregular uterine bleeding, as a hormone replacement therapy in postmenopausal women, as well as evaluation of androgen and estrogen production.
Mechanism of action
This drug has progestin, androgenic and glucocorticoid properties.
Pharmacokinetics
The half-life of the drug is about 16-24 hours. Drug metabolism is mainly hepatic and most of it is excreted in the feces.
Contraindications
This drug should not be used in case of pregnancy, vaginal bleeding, liver disorders or active liver disease, acute arterial disease, breast or genital cancer, as well as porphyria.
Warnings
Delayed corpus luteum function is seen following discontinuation of injectable medroxyprogesterone, especially in obese women. In diabetics, people with high blood pressure or heart and kidney disease should be prescribed with caution. In case of decreased vision, exophthalmos, diplopia, migraine and thrombotic disorder, all progestins should be discontinued. In women who have used this drug to prevent pregnancy, it is not possible to conceive for an average of 10 months after stopping the use. Women under the age of 35 who take birth control pills have an increased risk of breast cancer during the first 4 years of use.
Side effects
Swelling of the face, knees and legs can be seen with large amounts of medication. Other side effects include acne, urticaria, water retention, altered libido, breast discomfort, premenstrual symptoms, irregular menstrual bleeding, depression, insomnia, baldness and hair loss, hair loss and anaphylactoid-like reaction.
Recommendations
If pregnancy is suspected, the drug should be discontinued immediately.
Dosage or Ora
In the control of secondary amenorrhea, 5-10 mg / day is prescribed for 5-10 days, which can be taken at any time of the menstrual period. In non-functional uterine bleeding, 5-10 mg / day is prescribed for 5-10 days, which should start from the 16th or 21st day of menstruation. To stimulate menstruation, 10 mg / day is used for 10 days, starting from the 16th day of the cycle. In endometrial and renal cell carcinoma, it is initially given 400-400 mg once a week and its maintenance dose is 400 mg or more once a month. In postmenopausal breast cancer, 400 mg / day is used in divided doses. In endometriosis, 10-40 mg / day is used for 6-9 months. To evaluate estrogen and androgen secretion, 10 mg / day is used for 5-10 days. In the treatment of endometrial hyperplasia, 10 mg / day is used for 3-6 months. For hormonal replacement therapy in postmenopausal women, 5-10 mg / day is prescribed for 10-14 days in the first menstrual period along with estrogen.
Injection
Was this helpful?
0 / 0
